Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: betty moyers who wrote (21323)	4/24/1999 11:10:00 AM
From: Frostman	Read Replies (2) \| Respond to of 23519

Betty, Agree that Alibra would be hard to OTC, femme-cream, maybe pre-jack has a good chance all things considered, also will catch the street's imagination and run the price as did Muse in the "anticipation" stage before it was FDA approved. My single biggest concern is competition. Firstest with the mostest: got to have a credible product and presence... IR & marketing. Last price Vivus Germany $4.25 US converted. Cool enough. Frostman PS- New people here, welcome, long or short. I suggest you go back and spot-read a few of the 20K plus posts here, and on the two or three other Vivus threads.